Eyecare news update

Luneau Technology have merged with Optovue Global Inc. ‘creating a complete offering for eyecare physicians and transforming access to visual health for patients.’ Dr Marc Abitbol, CEO of Luneau Technology said of the merger “… our expertise is very complementary. What we’re doing now is uniting these two technologies to bring smarter, better, higher-precision solutions to the market.” Meanwhile, Peter Wyles, CEO of Optovue said “We are thrilled to work together toward our common vision, while at the same time, significantly optimizing the customer experience”.

Genentech have announced that the FDA has approved Susvimo 100 mg/mL for intravitreal use, via ocular implant, to treat people with wet age-related macular degeneration. This is the first and only FDA-approved treatment for wet AMD that offers as few as two treatments per year. “Susvimo represents a major advancement in the treatment of retinal disease and is an important new option for patients with wet AMD,” Carl Regillo, MD, Chief of Retina Service at Wills Eye Hospital.